RAYSUT-CEMENT-COMPANY
17.5.2021 14:01:06 CEST | Business Wire | Press release
In a significant endorsement that will support exports to European Union (EU) markets, Oman’s largest cement manufacturer, Raysut Cement Company (RCC), has received CE and NF certifications, two stringent global quality norms validating RCC’s adherence to EU standards in cement production.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005501/en/
The Muscat Stock Market (MSM)-listed RCC said the certifications come at a time when it is expanding exports to newer global markets. Currently, 50 per cent of the company’s output is exported to East Africa, India, Maldives, South Africa, and Indian Ocean islands.
“We consider CE and NF certifications a testimony to our commitment to constantly improve product quality and processes in line with rigorous global safety, quality and environmental regulations,” said Group CEO, Joey Ghose.
The CE (Conformité Européenne) mark, formerly EC mark, is mandatory for selling certain products in the European Economic Area (EEA) since 1985. The NF Mark from AFNOR certification entity is a French compliance norm that ensures product safety, quality, usage ability and performance.
“The certifications fit into our export strategy for newer geographies as the CE Mark that endorses compliance with EU’s health, safety and green regulations allows us to market our products in Iceland, Liechtenstein and Norway,” said Mr. Ghose.
Winning the certifications also coincided with RCC clinching a new export order from the Reunion Islands in the western Indian Ocean, and an annual contract has already been signed with Enterprise Audemard Group of the French island to ship 8,000 MT cement every month. The first shipment has been received by the party. RCC is also looking at setting up a grinding unit in Madagascar to leverage the 7-8 per cent Y-o-Y growth in that country’s market.
RCC has a current output of 6 million metric tonnes of cement, slated to increase to 10 million by 2022, and later to 22 million tonnes. Mr. Ghose said the COVID-19 pandemic has thrown a major challenge to the business, but RCC was facing it successfully with no change in leadership or vision.
Recently, RCC had won certifications from other parts of the world, boosting its export scope. These are from BIS (Bureau of Indian Standards), enabling it to stabilize its presence in India, and from SABPS (South African All Brothers Products and Systems) to help RCC leverage the South African market.
Mr. Salim bin Ahmed bin Alawi Al Ibrahim, Acting Deputy Group CEO of RCC said: “The cement now produced at RCC’s Salalah plant has accomplished the strictest environmental criterion of Hexavalent Chromium (Cr6+) content of less than two parts per million. The NF certification also opens up new market opportunities and we are now introducing a superior quality cement brand to the French colonies in the Indian Ocean Reunion Islands.”
Last year RCC won the ‘CEO of the Year’ honour for its Group CEO Mr. Joey Ghose, at both the Oman Best Employer Awards and GCC Best Employer Awards from Employer Branding Institute, which reinforced the company’s excellence across leadership, health and safety, technology, training and talent management.
“We regularly train our employees through on-the-job and by sending them overseas to upgrade their skills. This training helps us strictly implement quality, environmental and safety norms at our production facilities to improve our products in line with global demand,” added Mr. Al Ibrahim.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
